Menu Search
Equities

Protagonist Therapeutics Inc

PGF:BER

Protagonist Therapeutics Inc

Actions
  • Price (EUR)40.60
  • Today's Change-0.600 / -1.46%
  • Shares traded545.00
  • 1 Year change+144.58%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 19:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Protagonist Therapeutics Inc grew revenues 125.73% from 26.58m to 60.00m while net income improved from a loss of 127.39m to a smaller loss of 78.96m.
Gross margin--
Net profit margin53.26%
Operating margin47.71%
Return on assets36.35%
Return on equity40.69%
Return on investment39.20%
More ▼

Cash flow in USDView more

In 2023, Protagonist Therapeutics Inc increased its cash reserves by 48.41%, or 60.98m. Cash Flow from Financing totalled 170.48m or 284.13% of revenues. In addition the company used 70.24m for operations while cash used for investing totalled 39.26m.
Cash flow per share2.80
Price/Cash flow per share15.43
Book value per share9.21
Tangible book value per share9.21
More ▼

Balance sheet in USDView more

Protagonist Therapeutics Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio13.73
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.